Generic Name and Formulations:
Fluorometholone 0.1%; oph susp; contains benzalkonium chloride.
Indications for FML:
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1 drop 2–4 times daily or small amount of ointment 1–3 times daily. May give every 4 hours for 1st 24–48 hrs. Reevaluate after 2 days.
Fungal, mycobacterial, viral (except herpes zoster), or untreated bacterial infections.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections and intraocular pressure in prolonged use. Avoid abrupt cessation. May mask or exacerbate infections. Pregnancy (Cat.C). Nursing mothers: not recommended.
Ocular irritation, increased intraocular pressure with possible glaucoma, infrequent optic nerve damage, cataracts, delayed wound healing; systemic hypercorticoidism (rare).
Susp—5mL, 10mL, 15mL; Oint—3.5g; Forte—5mL, 10mL, 15mL
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
- Smoking Promotes Disease Progression in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored